WHiTE 9

  • Research type

    Research Study

  • Full title

    WHiTE 9: World Hip Trauma Evaluation 9; Blood Cell Salvage Trial A multi centre randomised controlled trial comparing intra operative cell salvage with standard care in the treatment of hip fractures.

  • IRAS ID

    256241

  • Contact name

    Damian Griffin

  • Contact email

    Damian.Griffin@warwick.ac.uk

  • Sponsor organisation

    University Hospitals Coventry & Warwickshire NHS Trust

  • ISRCTN Number

    ISRCTN15945622

  • Clinicaltrials.gov Identifier

    19/WA/0197 , Wales Research Ethics Committee 5

  • Duration of Study in the UK

    1 years, 6 months, 1 days

  • Research summary

    Patients admitted with a hip fracture are typically elderly, frail and have multiple medical co-morbidities, including anaemia. As a consequence of the fracture and urgent surgery, patients sustain acute blood loss, compounding this pre-existing anaemia. In patients with a fractured hip allogenic (blood from a donor) blood transfusion is required in up to 30% of patients.
    Blood transfusions impose some risks to patients, such as an increased rate infection. Allogenic blood use is associated with transfusion reactions and an increased length of hospital stay.
    Concerns regarding patient safety and the costs of allogenic blood have driven efforts to reduce transfusion rates. Intra operative cell salvage and autotransfusion is a method of collecting blood lost during surgery and transfusing it back to the patient. The cell salvage device separates oxygen carrying red blood cells lost during surgery, prior to transfusing them back to the patient. Complications as a result of cell salvage are rare.
    Patients with a hip fracture have a high mortality rate, high transfusion rates and high degrees of pre-existing conditions including anaemia. Therefore, despite not currently being used routinely, there are large potential benefits of using cell salvage in this population.
    We propose evaluating the clinical effectiveness of cell salvage in hip fracture surgery. Prior to assessing this in a definitive clinical trial we need to understand if surgeons and patients are willing to participate in such a study, and if sufficient blood is lost during surgery to make cell salvage viable.

  • REC name

    Wales REC 5

  • REC reference

    19/WA/0197

  • Date of REC Opinion

    15 Aug 2019

  • REC opinion

    Further Information Favourable Opinion